By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
When Lou Schmukler joined Bristol-Myers Squibb (BMS) in 2011, it was analogous to jumping onto a moving train. The company’s biopharma transformation was barreling ahead at full steam. Launched in 2007, the business strategy to take the best of biotech and best of pharma had reshaped BMS from a big, diversified pharmaceutical company into a focused specialty biopharma firm, and they weren’t done yet. More change was coming, and the company’s manufacturing operations would need to move fast to keep up.